In this article, we will discuss the Top 10 Large Cap Value Stocks to Buy Now.
On June 9, Tom Lee, Fundstrat Managing Partner, appeared on CNBC’s ‘Power Lunch’ to discuss the latest market action. Analyzing the sharp differences in market performance between the previous Friday and the current day, Lee explained that investors have been worried about the air gap because many stocks moved upward very quickly, leading to three specific jitters emerging last week: concerns regarding the strength of the AI trade following guidance from Broadcom; the realization that the public is being asked to fund a massive amount of equity (including $80 billion from Google, $75 billion from SpaceX, $100 billion from OpenAI, $75 billion from Anthropic), and a filing from Meta; and geopolitical tensions, specifically nervousness regarding potential conflict in Iran over the weekend. Despite these pullbacks, Lee maintains that the bull market is in very good shape and remains intact
Regarding the broader stock market, while some Mag 7 stocks are down and the Dow is slightly lower, the Nasdaq 100 remains up 2%, and the averages have recovered. Discussing whether the market ending the day lower after a morning boom would change his outlook, Lee explained that markets will face tension until June 12th because a large group of his institutional investor clients believe that the SpaceX IPO will mark the market top, leading them to take profits and act cautiously. Lee contends that these concerns are misplaced, arguing that history shows big IPOs do not necessarily mark the market top. He pointed out that there is still $7 trillion in cash on the sidelines and that the book for the IPO is already filled by high-net-worth clients. Consequently, he believes that the market will not only absorb the IPO well but will also perform well post-IPO.
Our Methodology
We used screeners to identify stocks with market caps between $10 billion and $200 billion that are trading below a forward P/E of 15, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on June 8.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
Top 10 Large Cap Value Stocks to Buy Now
10. Banco Santander (NYSE:SAN)
Number of Hedge Fund Holders: 25
Banco Santander (NYSE:SAN) is one of the top large cap value stocks to buy now. On May 5, Banco Santander and Uber announced a strategic partnership to launch a financing platform of up to €1 billion designed to support Uber’s major fleet operators across Europe. This three-year funding initiative aims to provide professional operators in key markets, including Spain, Germany, and Italy, with the flexible capital needed to scale their businesses and modernize their fleets.
The program is tailored to the specific financial requirements of fleet operators, helping them optimize performance and maintain service reliability for riders. Beyond immediate growth, the collaboration is intended to lay a stronger foundation for Uber’s long-term objectives, including the future integration of autonomous vehicle technology and broader urban mobility expansion.
Santander Executive Chair Ana Botín highlighted the bank’s role in supporting service quality and scalability. At the same time, Uber CEO Dara Khosrowshahi noted that the platform will enable partners to upgrade vehicles and operate more efficiently. The financing will be deployed gradually based on market demand, risk analysis, and the ongoing onboarding of high-quality fleet partners.
Banco Santander (NYSE:SAN) is a Spain-based company that operates as a retail and commercial bank. Its segments are scattered across Continental Europe, the UK, Latin America, and the US.
9. TotalEnergies (NYSE:TTE)
Number of Hedge Fund Holders: 30
TotalEnergies (NYSE:TTE) is one of the top large cap value stocks to buy now. On May 12, TotalEnergies, in partnership with QatarEnergy and ConocoPhillips, signed an MoU with the Syrian Petroleum Company to explore Block 3 offshore in the Mediterranean Sea. The agreement initiates a technical review of the area and establishes a formal framework for future technical and commercial discussions regarding potential exploration activities.
Julien Pouget, Senior Vice President for the Middle East and North Africa at TotalEnergies, expressed satisfaction at renewing the partnership with the Syrian Petroleum Company, citing their long-standing collaboration from 1988 to 2011. The company plans to work closely with its partners to evaluate the potential for offshore exploration within the region.
This move aligns with TotalEnergies’ (NYSE:TTE) global strategy as an integrated energy company focused on producing and marketing a diverse range of energy sources. Operating in ~120 countries, the firm continues to prioritize sustainability across its projects while seeking to provide reliable and affordable energy solutions worldwide.
TotalEnergies (NYSE:TTE) is a global multi-energy company that produces and markets oil, biofuels, natural gas, renewables, and electricity.
8. Rio Tinto (NYSE:RIO)
Number of Hedge Fund Holders: 40
Rio Tinto (NYSE:RIO) is one of the top large cap value stocks to buy now. On June 1, Sandvik entered into a collaboration with Rio Tinto to develop and integrate its i-series surface drill rigs with Rio Tinto’s existing Autonomous Drilling System. By combining Sandvik’s AutoMine automation technology with Rio Tinto’s experience in remote operations, the partnership aims to enhance safety, productivity, and system interoperability across open-pit mining environments.
The development process will be managed through Rio Tinto’s Operations Centre in Perth, starting with testing at Sandvik’s test facility in Finland. These initial phases will be followed by site-based field trials at Rio Tinto’s operations in Western Australia, where the companies will assess the technology’s performance against specific production targets.
This project builds upon existing autonomous infrastructure at Rio Tinto’s (NYSE:RIO) iron ore sites and reflects Sandvik’s focus on scalable, interoperable automation. The collaboration comes as both companies pursue separate growth initiatives, including Sandvik’s recent equipment orders for copper mine projects and Rio Tinto’s ongoing $1.5 billion smelter expansion in Quebec, which is expected to conclude by the end of 2026.
Rio Tinto (NYSE:RIO) is a diversified global mining company that engages in exploring, mining, and processing mineral resources worldwide.
7. Novo Nordisk (NYSE:NVO)
Number of Hedge Fund Holders: 55
Novo Nordisk (NYSE:NVO) is one of the top large cap value stocks to buy now. On June 8, Novo Nordisk presented Phase 3 results from its REIMAGINE 1–3 clinical program at the 2026 American Diabetes Association Scientific Sessions. The trials showed that the investigational treatment CagriSem, a once-weekly combination of an amylin analog and a GLP-1 receptor agonist, achieved significant, consistent reductions in both HbA1c levels and body weight across diverse groups of adults with type 2 diabetes.
This combination therapy leverages the synergistic effects of two distinct hormonal pathways to improve glucose regulation and appetite control. Novo Nordisk’s Chief Scientific Officer, Martin Holst Lange, highlighted the therapy’s potential to become a first-in-class treatment option, showing promise for patients at various stages of diabetes management, ranging from initial therapy to insulin add-on.
The findings, simultaneously published in The Lancet and The Lancet Diabetes & Endocrinology, follow previous data from the REDEFINE program. By addressing multiple pathways of metabolic health, the REIMAGINE trials validate the clinical utility of pairing cagrilintide with semaglutide, offering a potential new strategy for patients who may require advanced approaches to managing their diabetes.
Novo Nordisk (NYSE:NVO) is a drug manufacturer for global pharmaceutical products that operates through two segments: Obesity & Diabetes Care and Rare Disease. The company was founded in 1923 and is headquartered in Denmark.
6. Amgen Inc. (NASDAQ:AMGN)
Number of Hedge Fund Holders: 65
Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data from the VESALIUS-CV trial at the American Diabetes Association’s 86th Scientific Sessions, demonstrating that Repatha significantly reduces cardiovascular risk in patients with high-risk diabetes. In a subgroup of 6,002 patients with elevated LDL-C but no history of heart attack or stroke, the addition of Repatha to existing lipid-lowering therapies reduced the risk of major adverse cardiovascular events by 29% compared to a placebo.
Dr. Jay Bradner, Amgen’s EVP of Research and Development, emphasized that early and intensive LDL-C reduction is vital for preventing cardiovascular events in this vulnerable population. The findings held consistent regardless of whether patients were concurrently using SGLT2 inhibitors or GLP-1 receptor agonists, underscoring the necessity of managing multiple risk factors, particularly uncontrolled LDL-C, in individuals living with diabetes.
Beyond the VESALIUS-CV results, Amgen shared real-world evidence identifying significant treatment gaps in current diabetes and obesity care. Studies indicated that low treatment persistence and adherence to GLP-1 therapies often lead to less effective outcomes in clinical practice than those observed in trials. Amgen Inc. (NASDAQ:AMGN) noted that these findings highlight a critical need for new care strategies and treatment approaches that help patients sustain therapy to achieve long-term metabolic health goals.
Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the Top 5 Large Cap Value Stocks to Buy Now.
Disclosure: None. None. Follow Insider Monkey on Google News.
